BCM
VTGN icon

BML Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

BML Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$533K – 24
2025
Q3 		$533K Hold
150,000
– – 0.49% 15
2025
Q2 		$300K Hold
150,000
– – 0.23% 22
2025
Q1 		$375K Hold
150,000
– – 0.3% 22
2024
Q4 		$443K Hold
150,000
– – 0.27% 19
2024
Q3 		$452K Hold
150,000
– – 0.27% 25
2024
Q2 		$522K Hold
150,000
– – 0.37% 24
2024
Q1 		$792K Hold
150,000
– – 0.52% 26
2023
Q4 		$771K Buy
150,000
+50,000
+50% +$189K 0.58% 24
2023
Q3 		$524K Buy
+100,000
New +$444K 0.48% 19

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BML Capital Management's VTGN Position: Q4 2025 in Review

BML Capital Management sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 150,000 shares — an estimated $533K sold.

BML Capital Management first reported a position in VTGN in Q3 2023 and held it in 9 quarters. The position peaked at $792K in Q1 2024. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • BML Capital Management reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BML Capital Management sold 150,000 VistaGen Therapeutics shares in Q4 2025, an estimated $533K.
  • BML Capital Management first reported a position in VistaGen Therapeutics in Q3 2023 and held it in 9 quarters.
  • BML Capital Management's VistaGen Therapeutics position peaked at $792K in Q1 2024.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on BML Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.